Salvage high-intensity focused ultrasound for locally recurrent prostate cancer after low-dose-rate brachytherapy: oncologic and functional outcomes.

To evaluate the oncologic and functional outcomes of salvage high-intensity focused ultrasound (S-HIFU) for locally recurrent prostate cancer after low-dose rate brachytherapy.

Clinical phase II studies (2003-2015) included 50 consecutive patients with post-brachytherapy local recurrence treated by S-HIFU. S-HIFU was performed with post-external beam radiotherapy parameters and, since 2008, with specific post-brachytherapy parameters. Treatments were whole-gland ablation and, since 2009, hemiablation in cases of unilateral prostate cancer. The primary objective was to assess oncological outcomes: treatment failure-free survival, progression free survival, overall survival, cancer-specific survival and metastasis-free survival rates. The secondary objective was to evaluate adverse events, continence, and erectile function. Kaplan-Meier analysis estimated oncologic outcomes.

Thirteen patients were treated with post-external beam radiotherapy parameters, 37 with post-brachytherapy parameters, 35 with whole-gland treatment, and15 with hemiablation. The median follow-up was 4.6 years. After S-HIFU, the median prostate specific antigen was 0.3 ng/ml. At 6 years, treatment failure free survival, progression-free survival, overall survival, cancer-specific survival, and metastasis-free survival rates were 41%, 45%, 93%, 98% and 80%, respectively. Post-brachytherapy compared with post-external beam radiotherapy parameters reduced grade 2-3 incontinence (34% vs 62%, p=0.015). Incontinence, bladder outlet obstruction and grade ≥ III complications were significantly reduced with hemiablation compared with whole-gland treatment (14% vs 54%, p < 0.001; 13% vs 46%, p=0.03; 13% vs 63% p=0.001, respectively). Before S-HIFU, 25 patients had an International Index of Erectile Function-5 ≥ 17, which was maintained in 48% at 12 months.

Salvage HIFU for locally recurrent prostate cancer after low-dose rate brachytherapy is associated with favourable survival rates at a price of significant morbidity. Dedicated post-brachytherapy parameters and hemiablation improve the safety of the treatment. This article is protected by copyright. All rights reserved.

BJU international. 2019 May 30 [Epub ahead of print]

Thomas Hostiou, Albert Gelet, Jean-Yves Chapelon, Olivier Rouvière, Florence Mège-Lechevalier, Cyril Lafon, Hélène Tonoli-Catez, Lionel Badet, Sébastien Crouzet

Department of Urology and Transplantation Surgery, Edouard Herriot Hospital, Lyon, France.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe